Deutsche Bank has set a price target of DKK290 on Novo Nordisk (NYSE: NVO), representing just 3.6% upside from the last closing price of DKK280.10, while maintaining a hold rating on the stock.
The bank expects the company’s pending ZEUS trial to miss, though it acknowledges low confidence in that prediction, pointing to genuine uncertainty surrounding the trial’s outcome.
The ZEUS trial is testing ziltivekimab, known as zilte, a drug being developed to treat chronic inflammation, which Novo is counting on as a potential growth driver.
Market expectations for the trial result are already low, both explicitly in analyst forecasts and implicitly in how the stock is currently priced, according to Deutsche Bank.
Novo faces a roughly $30 billion patent cliff in 2031, when key revenue-generating drugs lose patent protection, a challenge the bank views as unlikely to be meaningfully addressed by zilte.
Even in a scenario where the trial succeeds, Deutsche Bank believes the magnitude of that success would be unlikely to materially change the company’s longer-term financial outlook.
The bank describes a “blue-sky” best-case scenario in which zilte could help offset some of the patent cliff impact, but views this outcome as highly unlikely given current evidence.
Deutsche Bank also flags the trial as potentially a “sell the news” event, meaning investors may choose to sell into any positive announcement rather than treating it as a genuine catalyst for share price appreciation.
The combination of low odds of trial success, limited near-term commercial potential even in a positive outcome, and the scale of the 2031 patent cliff suggests Novo’s fundamental challenges extend well beyond the ZEUS result.
For investors, the trial outcome may ultimately prove less significant than the company’s ability to develop new blockbuster drugs capable of replacing the revenue set to be lost when key patents expire.
The pressure on Novo to fill that pipeline gap is mounting, with the clock ticking toward a patent expiration event that could reshape the company’s revenue base in just five years.
